

Statement of Audited Standalone Financial Results for the Quarter & Year Ended on 31/03/2020

Rs. In Lacs other than EPS

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31-03-2020	31-12-2019	31-03-2019	31-03-2020	31-03-2019
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue from Operations	3027.76	3359.46	3512.59	11889.09	12264.43
2	Other Income	128.70	83.38	93.24	421.83	340.97
3	Total income	3156.46	3442.84	3605.83	12310.92	12605.40
4	Expenses					
	(a) Cost of Materials Consumed	221.86	256.92	233.92	965.21	1184.31
	(b) Purchase of Stock-in-trade	427.45	657.85	780.01	2390.22	2690.71
	(c) Changes in inventories of Finished Goods, Stock-in-trade and WIP	89.81	16.44	-59.71	-48.74	-249.39
	(d) Employee benefit expenses	947.92	907.18	821.83	3651.02	3120.49
	(e) Finance Costs	12.14	14.36	9.62	52.56	38.59
	(f) Depreciation and Amortisation Expense	56.93	66.44	35.16	229.93	135.30
	(g) Other expenses	711.43	856.45	845.78	2956.94	3022.05
	Total Expenses	2467.54	2775.64	2666.61	10197.14	9942.06
5	Profit before exceptional items & Tax	688.92	667.20	939.22	2113.78	2663.34
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00
7	Profit before tax	688.92	667.20	939.22	2113.78	2663.34
8	Tax Expense					
	(i) Current Tax	176.00	200.00	252.00	576.00	752.00
	(ii) Income Tax for previous years	12.10	0.00	0.00	13.89	-37.52
	(ii) Deferred Tax	39.17	3.32	-2.23	36.93	-30.92
9	Profit after tax for the period	461.65	463.88	689.45	1486.96	1979.78
10	Other Comprehensive Income					
	(i) Items that will not be reclassified to profit or loss	-234.29	21.98	-44.97	-209.68	-44.97
	(ii) Income Tax relating to Items that will not be reclassified to profit or loss	-27.16	3.45	17.68	-23.70	17.68
	(iii) Items that will be reclassified to profit or loss	0.00	0.00	-8.79	0.00	0.00
	(iv) Income Tax relating to Items that will be reclassified to profit or loss	0.00	0.00	12.20	0.00	0.00
11	Total Comprehensive Income for the period	200.20	489.31	665.57	1253.57	1952.49
12	Paid up Equity Share Capital (F.V. Rs.10/- each)	458.94	458.94	458.94	458.94	458.94
13	Earnings Per Share (in Rs.) (F.V. Rs.10/-) Basic and Diluted	10.06	10.11	15.02	32.40	43.14



Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai

Notes:

- 1 The above statement of audited standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meeting held on June 30, 2020.
- 2 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable.
- 3 The figures for the quarter ended on 31.03.2020 are the balancing figures between audited figures for the year ended on 31.03.2020 and published year to date figures upto the third quarter ended on 31.12.2019.
- 4 The figures of the previous year/period have been regrouped/rearranged to render them comparable with figures of the current period.
- 5 In the current year from 1st April 2019 the company has changed the method of valuation of finished goods and work in progress from batch costing method to weighted average cost method. Thus the own-manufactured stock for the period ended 31st March 2020 is stated at weighted average cost, whereas the corresponding stock for the previous year is valued as per batch costing method. The financial impact of the change in method of stock valuation from batch costing method to weighted average method for the period ended 31st March 2020 is as follows.

Inventory under Batch Costing Method	220.79
Inventory of OMG under Weighted Average Method	210.96
Effect of increase/ decrease in COGS	9.83
- 6 In the current year from 1st April 2019 the company has changed the method of valuation of Raw Material, Packing Material & Stock In Trade from FIFO method to weighted average cost method. Thus the stock for the period ended 31st March 2020 is stated at weighted average cost, whereas the corresponding stock for the previous year is valued as per FIFO method. The financial impact of the change in method of stock valuation from FIFO method to weighted average method for the period ended 31st March 2020 is as follows.

Inventory under Batch Costing Method	876.12
Inventory of OMG under Weighted Average Method	878.91
Effect of increase/ decrease in COGS	(2.79)
- 7 The financial impact of the change in method of stock valuation from Batch Costing & FIFO method to weighted average method on Retained Earnings & Tax payable for the period ended 31st March 2020 is as follows.

Retained earning under Batch Costing / FIFO Method	2,120.81
Retained earnings under Weighted Average Method	2,113.78
Increase / Decrease in Retained earnings	7.03
- 8 The Statement of assets & liabilities as on 31.03.2020 is as per annexure A
- 9 Cashflow Statement as on 31.03.2020 is as per annexure B

Place : Mumbai
Date : June 30, 2020



By order of the Board
For Jenburkt Pharmaceuticals Ltd.

(ASHISH U BHUTA)
CHAIRMAN AND MANAGING DIRECTOR

 Science hai toh Hope hai  Hope hai toh Health hai  Health hai toh Happiness hai 

Annexure - A
Statement of Standalone Assets & Liabilities

			Rs in Lacs		
		Particulars	Note	31/03/2020	31/03/2019
				(Audited)	(Audited)
		ASSETS			
(1)		Non Current Assets			
	(a)	Property, Plants & Equipments	1	890.00	903.14
	(b)	Right to Use Asset	1	198.51	40.02
	(c)	Goodwill	2	0.14	0.14
	(d)	Other Intangible assets	2	84.13	15.89
	(e)	Capital Work In Progress	2	11.81	99.00
	(f)	Financial Assets			
	(i)	Investments	3	249.67	185.61
	(iii)	Loans	4	6.98	16.78
	(f)	Deferred tax assets (Net)	5	(23.82)	36.82
	(g)	Other non-current assets	6	35.28	18.31
(2)		Current assets			
	(a)	Inventories	7	1,089.87	983.12
	(b)	Financial Assets			
	(i)	Investments	8	157.19	352.11
	(ii)	Trade receivables	9	1,782.98	2,289.49
	(iii)	Cash and cash equivalents	10	253.40	122.68
	(iv)	Bank balance other than (iii)	11	5,515.73	5,047.33
	(v)	Loans	12	21.86	31.64
	(vi)	Others	13	27.96	59.80
	(c)	Other current assets	14	105.28	80.63
		Total Assets		10,406.98	10,282.49
		EQUITY AND LIABILITIES			
		Equity			
	(a)	Equity Share capital	15	458.94	458.94
	(b)	Other Equity - Reserves & Surplus	16	7,541.49	7,287.61
		LIABILITIES			
(1)		Non current liabilities			
	(a)	Other non-current liabilities	17	426.46	274.38
(2)		Current Liabilities			
	(a)	Financial Liabilities			
	(i)	Borrowings	18	343.89	746.94
	(ii)	Trade payables			
	(A)	Total outstanding dues of Micro Enterprises and Small Enterprises; and	19	1.85	21.49
	(B)	Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises.	19	520.79	633.41
	(iii)	Other financial liabilities	20	621.05	626.92
	(b)	Other current liabilities	21	231.14	177.86
	(c)	Provisions	22	217.31	41.52
	(d)	Current tax liabilities (Net)	23	44.05	13.42
		Total Equity and Liabilities		10,406.98	10,282.49

Place : Mumbai
Date : June 30, 2020



By order of the Board
For Jenburkt Pharmaceuticals Ltd.

Ashish U. Bhuta
(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

for

Annexure - B
Cashflow Statement as on 31/03/2020

Rs in Lacs

			31-03-2020	31/03/2019
A.		CASH FLOW FROM OPERATING ACTIVITIES :		
	a	Net Profit before tax	2,113.78	2,663.34
		Adjustments for :		
	i	Depreciation and Amortisation Expense	229.93	135.31
	ii	Profit on sale/written off of property, plant and equipment and intangible assets, net	-	3.48
	iii	Finance Cost	52.56	38.59
	iv	Interest Income	(363.53)	(320.50)
	v	Dividend income	(4.86)	(23.37)
	vi	Gain on sale of Investment (Short/Long Term Capital Gain)	-	-
	vii	Provision/write off for doubtful trade receivables/advances	-	0.34
	viii	Net unrealised foreign exchange gain	(36.52)	1.28
		Operating profit (Loss) before working capital changes	1,991.36	2,498.47
	b	MOVEMENTS IN WORKING CAPITAL		
	i	Increase or (Decrease) in Inventories	(106.75)	(302.68)
	ii	Increase or (Decrease) in Trade Receivables	506.51	(1,036.05)
	iii	Increase or (Decrease) in Other (Current & Non Current) Assets	(9.79)	5.26
	iv	Increase or (Decrease) in Trade Payables	(132.25)	242.69
	v	Increase or (Decrease) in Bank Borrowings	(403.05)	723.34
	vi	Increase or (Decrease) in Other (Current & Non Current) Liabilities	236.01	(67.87)
	vii	Increase or (Decrease) in Provisions	(33.89)	(54.80)
	c	Cash used in operation	2,048.16	2,008.37
	i	Income Taxes paid (Net of Refund)	(546.47)	(709.68)
		Net cash used in operating activities (A)	1,501.68	1,298.68
B.		CASH FLOW FROM INVESTING ACTIVITIES :		
	i	Payments for purchase of Property, Plant and Equipment (Including Capital Work in Progress, Intangible Assets and Intangible Assets in Development)	(455.44)	(240.14)
	ii	Proceeds from disposal of property, plant and equipment and intangible assets	99.10	0.00
	iii	Purchase of Investments	(2,125.79)	(5,010.66)
	iv	Proceeds from Sale / Redemption of Investments	2,256.65	5,047.29
	v	Other Bank balances not considered as cash and cash equivalents		
		Bank Fixed Deposit made during the year	(5,172.48)	(3,750.25)
		Bank Fixed Deposit matured during the year	4,885.55	2,611.36
	vi	Current & Non Current Financial Loans (Net employee loans given / recovered)	19.59	(9.27)
	vii	Interest Received	200.40	275.68
	viii	Dividend Received	4.86	23.37
		Net cash generated by investing activities (B)	(287.57)	(1,052.63)
C.		CASH FLOW FROM FINANCING ACTIVITIES :		
	i	Borrowings - Others	-	(0.53)
	ii	Finance Cost	(52.56)	(38.59)
	iii	Dividend paid	(858.19)	(146.00)
	iv	Tax on Dividend paid	(172.64)	(56.61)
	v	Payment towards Buyback with premium	-	-
		Net cash used in financing activities (C)	(1,083.39)	(241.74)
		NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENT (A+B+C)	130.72	4.31
		Cash and cash equivalent at the beginning of the year (1st April, 2019)	122.68	118.37
		Cash and cash equivalent as at the end of the year (31st March, 2020)	253.40	122.68
			130.72	4.31

By order of the Board
For Jenburkt Pharmaceuticals Ltd.



Ashish U. Bhuta

(ASHISH U BHUTA)

CHAIRMAN AND MANAGING DIRECTOR

Place : Mumbai
Date : June 30, 2020